Dr Nicole Haynes
Honorary Conjoint Senior Fellow
The Sir Peter MacCallum Department of Oncology
63 Scholarly works
3 Projects
HIGHLIGHTS
2026
Journal article
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
DOI: 10.1016/S1470-2045(26)00017-32026
Journal article
Striking the right balance with type I interferon signalling in cancer
DOI: 10.1038/s41568-026-00915-12025
Journal article
Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanoma
DOI: 10.1136/jitc-2025-0115512025
Journal article
CAR T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma
DOI: 10.1056/NEJMoa23097282025
Journal article
BRAF/MEK inhibition following immune checkpoint inhibitors promotes antitumor immunity associated with expansion of progenitor-exhausted CD8⁺ T cells
DOI: 10.1016/j.ejcskn.2025.1007372024
Journal article
Context-restricted PD-(L)1 checkpoint agonism by CTLA4-Ig therapies inhibits T cell activity
DOI: 10.1016/j.celrep.2024.1148342017
Research Grant
Combination of Radionuclide 177lu-Psma Therapy With Pembrolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc)
RECENT SCHOLARLY WORKS
2024
Journal article
The complexity of immune evasion mechanisms throughout the metastatic cascade
DOI: 10.1038/s41590-024-01960-42023
Journal article
CAR plus T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma
DOI: 10.1182/blood-2023-1788062023
Conference Proceedings
Cellular immunotherapy targeting kappa myeloma antigen for the treatment of multiple myeloma
DOI: 10.1158/1538-7445.AM2023-40742023
Journal article
Sequencing of targeted- and immune-therapy: delineating time dependent changes in both melanoma cells and the immune microenvironment
DOI: 10.1158/1538-7445.AM2023-5941
RECENT PROJECTS
2016
Research Grant
The Combination of Cdk4 and Mapk/Erk Pathway Inhibitor Therapy in Melanoma: Defining Melanoma Cell Intrinsic and Immune Mediated Responses
2013
Research Grant
Building Immunity to Breast Cancer With Radio-Immunotherapy Combinations